Bleeding and Clotting Disorders — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2024	Research	$1,080	2
2023	Research	$15,770	24
2022	Research	$24,268	42
2021	Research	$6,428	8
2019	Research	$806	2

Breakdown

Who paid Research payments · program years 2019–2024

Sobi, Inc $41,118 68 payments
Dova Pharmaceuticals $6,428 8 payments
Pfizer Inc. $806 2 payments

Studies the money was for Research payments · program years 2019–2024

Ava-Itp-401 $28,984 47 payments
Prospective, Multi-Center, Open-Label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (Itp) After Switching to Avatrombopag From Eltrombopag Or Romiplostim $12,134 21 payments
Prospective, Multi-center, Open-label Study Measuring Safety and Treatment Satisfaction in Adult Subjects With Chronic Immune Thrombocytopenia (ITP) After Switching to Avatrombopag From Eltrombopag or Romiplostim $6,428 8 payments
A Randomized Open Label Active Controlled Safety and Descriptive Efficacy Study in Pediatric Subjects Requiring Anticoagulation for the Treatment of A Venous Thromboembolic Event $806 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.